21 May 2009
Urinary iodine concentrations should be monitored to diagnose some thyroid gland diseases in heart transplant recipients
E Wozniak-Grygiel, A Cichoracka, S Zeglen, M Zakliczynski, M ZembalaAnn Transplant 2009; 14(1): 62-62 :: ID: 880424
Abstract
Background: According to WHO iodine excreted with urine is a measure
of its supply. Due to International Council for Control of Iodine Deficiency
Disorders (ICCIDD), the urinary iodine (UI) should be above 100 μg I per 1
L of urine. The moderate iodine deficiency (MID) occurs when UI is from 50
to 100 μg/L and the severe deficiency (SID) when UI is below 50 μg/L.
Material/Methods: UI analysis in 32 heart transplant recipients (26 men and 6
women; mean age 50.4±12.6 yr) by modified PAMM method (the spectrophotometric measurement based on the Sandell-Kolthoff reaction). Results were evaluated and compared with thyroid stimulating hormone (TSH; μIU/mL), free triiodothyronine (FT3; pg/mL) and thyroxin (FT4; ng/dL). Hormones were measured using a Microparticle Enzyme Immunoassay (MEIA).
Results: The average UI in the whole group was 126.4±109.6. Unfortunately,
SID in 12 patients (37.5%) and MID in 4 of them (12.5%) was noted (mean UI: 17.0±9.6 and 79.5±5.6, respectively). In the rest 16 patients (50%) average UI was high and amounted 220.1±72.1. TSH, FT3 and FT4 in the whole group were in the normal range. However, FT4 values significantly differed when SID and MID-patients were compared to those with recommended UI (0.8±0.2 and 0.9±0.1 vs. 1.1±0.2, p<0.05; respectively). Decreased values of TSH in 5 patients (15.6%) and FT3 or FT4 in 6 (18.8%) were noted.
Conclusions: Measurements of urinary iodine in heart transplant recipients
together with thyroid gland hormones may be essential to monitoring and
preventing thyroid gland abnormalities.
Keywords: Heart Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






